Anixa's ovarian cancer CAR-T inventor will deliver a November keynote as lira-cel advances through Phase 1 dose escalation. Preliminary findings include four patients surviving more than one year and an initial 90-day stable disease observation, but controlled efficacy evidence is not yet available.
Conventional CAR-T therapy turns one patient’s T cells into one personalized drug batch through collection, genetic engineering, expansion, testing and release. Faster autologous, allogeneic and in-vivo approaches are trying to collapse that process from weeks toward days.
Find out how Qihan Biotech’s QT-019B FDA designations could reshape autoimmune CAR-T development and what risks remain.
Find out how Cartesian Therapeutics’ WestGene deal could reshape in vivo CAR-T strategy in autoimmune disease and what risks remain.
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.